Eszopiclone for the Treatment of Posttraumatic Stress Disorder and Associated Insomnia: A Randomized, Double-Blind, Placebo-Controlled Trial
The DOI matches its Crossref record.
Abstract
Article Abstract Objective: The development of novel strategies for the treatment of posttraumatic stress disorder (PTSD) represents a critical public health need. We present the first prospective, randomized, double-blind, placebo-controlled trial of a non-benzodiazepine hypnotic agent for the treatment of PTSD and associated insomnia. Method: Twenty-four patients with PTSD by DSM-IV criteria and sleep disturbance were treated in a randomized, double-blind, placebo-controlled crossover study of 3 weeks of eszopiclone 3 mg at bedtime compared to placebo. The primary outcome measures were changes in scores on the Short PTSD Rating Interview (SPRINT) and the Pittsburgh Sleep Quality Index (PSQI). The data were collected from April 2006 to June 2008. Results: Three weeks of eszopiclone pharmacotherapy was associated with significantly greater improvement than placebo on PTSD symptom measures including the SPRINT (P = .032) and the Clinician-Administered PTSD Scale (P = .003), as well as on measures of sleep including the PSQI (P = .011) and sleep latency (P = .044). Greater improvement with eszopiclone on PTSD measures was present even when specific sleep-related items were excluded. Adverse events were consistent with the known profile of the drug. Conclusions: This study provides initial evidence that pharmacotherapy with eszopiclone may be associated with short-term improvement in overall PTSD severity as well as associated sleep disturbance. Longer, more definitive study of eszopiclone in PTSD is warranted. Trial Registration: clinicaltrials.gov Identifier: NCT00120250 J Clin Psychiatry 2011;72(7):892-897 Submitted: August 11, 2009; accepted December 17, 2009. Online ahead of print: February 22, 2010 (doi:10.4088/JCP.09m05607gry). Corresponding author: Mark H. Pollack, MD, Center for Anxiety and Traumatic Stress Disorders, Massachusetts General Hospital, One Bowdoin Square, Sixth Floor, Boston, MA 02114 (mpollack@partners.org).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“in improving PTSD and sleep symptoms (Level 2) [1055].”
BackgroundThe GABA system in anxiety and depression and its therapeutic potential
Möhler, H. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.040 · Cited by 590
Psychiatric Disorders and Sleep
Krystal, A. D. (2012) · Neurologic Clinics · doi:10.1016/j.ncl.2012.08.018 · Cited by 386
Health economics of insomnia treatments: The return on investment for a good night's sleep
Wickwire, E. M., Shaya, F. T., & Scharf, S. M. (2016) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2015.11.004 · Cited by 287
Krystal, J. H., Davis, L. L., Neylan, T. C., A. Raskind, M., Schnurr, P. P., Stein, M. B., Vessicchio, J., Shiner, B., Gleason, T. D., & Huang, G. D. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.03.007 · Cited by 265
“Furthermore, benzodiazepines, historically one of the medications most commonly prescribed in patients with PTSD, failed to show efficacy in small pilot studies (44,45) and interfered with fear extinction in another study (46); although one study with a hypnotic drug (eszopiclone) was positive (47).”
Background
Metadata
- Authors
- Pollack, M. H., Hoge, E. A., Worthington, J. J., Moshier, S. J., Wechsler, R. S., Brandes, M., & Simon, N. M.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2011-02-22
- Volume
- 72
- Issue
- 07
- Pages
- 892-897
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2082401600
- Cited by
- 101
- References
- 0
- FWCI
- 8.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Eszopiclone for the Treatment of Posttraumatic Stress Disorder and Associated Insomnia: A Randomized, Double-Blind, Placebo-Controlled Trial. https://app.cochat.ai/papers/10.4088/jcp.09m05607gry
- The paper
- Pollack, M. H., Hoge, E. A., Worthington, J. J., Moshier, S. J., Wechsler, R. S., Brandes, M., & Simon, N. M. (2011). Eszopiclone for the Treatment of Posttraumatic Stress Disorder and Associated Insomnia: A Randomized, Double-Blind, Placebo-Controlled Trial. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.09m05607gry
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.